9713 Key West Avenue
Suite 400
Rockville, MD 20850
United States
301 944 1700
https://www.maxcyte.com
Sector(s): Healthcare
Industry: Medical Devices
Full-time employees: 143
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. Douglas Arthur Doerfler | Founder | 2.34M | N/A | 1956 |
Mr. Douglas J. Swirsky CFA, CPA | Chief Financial Officer | 607.42k | N/A | 1969 |
Mr. Jay Gelfman | Senior Vice President of Operations | N/A | N/A | N/A |
Mr. Ronald Evan Holtz CPA, Ph.D. | Executive Vice President of Administration | 649.38k | N/A | 1958 |
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
MaxCyte, Inc.’s ISS governance QualityScore as of 1 May 2024 is 6. The pillar scores are Audit: 2; Board: 8; Shareholder rights: 8; Compensation: 7.